Klinische-studie

Diabetes Medications: SGLT2 Inhibitors and GLP-1 Agonists Reduce Alzheimer’s Risk by 43% and 33%

by

Recent clinical research indicates that patients with Type 2 diabetes treated with SGLT2 inhibitors may experience a significantly lower incidence of Alzheimer’s disease compared to those using other glucose-lowering medications. According to a large-scale study published in The BMJ, the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of dementia, suggesting … Read more

GLP-1 and Obesity Treatment: Metabolic Health, Long-Term Therapy, and Future Innovations

by

For decades, the global approach to treating obesity was framed primarily as a battle of willpower. Patients were told to “eat less and move more,” a mantra that often ignored the complex biological drivers of weight gain and the stubborn nature of metabolic adaptation. However, a pharmacological shift is currently underway, transforming obesity from a … Read more